Want to join the conversation?
$CHK 2Q15 Q&A: Brackett of Sanford asked about the source of $209MM marketing profit. Nick replied that it’s a mark-to-market of a marketing contract that CHK had and it’s treated like a derivative. That contract began its operation in 2Q15 and so Co. will take fair value measurement of future contract and it's in a significant gain position today.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.